Mirum Pharmaceuticals/$MIRM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Mirum Pharmaceuticals
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Ticker
$MIRM
Sector
Primary listing
Employees
349
Headquarters
Website
MIRM Metrics
BasicAdvanced
$3.7B
-
-$1.20
0.95
-
Price and volume
Market cap
$3.7B
Beta
0.95
52-week high
$78.10
52-week low
$36.86
Average daily volume
821K
Financial strength
Current ratio
3.131
Quick ratio
2.841
Long term debt to equity
124.165
Total debt to equity
124.981
Interest coverage (TTM)
-3.98%
Profitability
EBITDA (TTM)
-32.859
Gross margin (TTM)
79.02%
Net profit margin (TTM)
-13.65%
Operating margin (TTM)
-13.30%
Effective tax rate (TTM)
-2.10%
Revenue per employee (TTM)
$1,230,000
Management effectiveness
Return on assets (TTM)
-5.15%
Return on equity (TTM)
-24.19%
Valuation
Price to revenue (TTM)
8.422
Price to book
14.58
Price to tangible book (TTM)
215.17
Price to free cash flow (TTM)
-2,632.399
Free cash flow yield (TTM)
-0.04%
Free cash flow per share (TTM)
-0.028
Growth
Revenue change (TTM)
62.33%
Earnings per share change (TTM)
-49.89%
3-year revenue growth (CAGR)
123.36%
3-year earnings per share growth (CAGR)
-10.99%
What the Analysts think about MIRM
Analyst ratings (Buy, Hold, Sell) for Mirum Pharmaceuticals stock.
Bulls say / Bears say
Mirum delivered robust Q2 2025 commercial performance with total revenue of $127.8 million (up 64.1% YoY) and Livmarli net product sales of $88.2 million (up 87% YoY), significantly beating expectations and prompting an upward revision to 2025 guidance (Nasdaq).
The U.S. launch of the single oral tablet dose of Livmarli in June 2025 contributed $57 million in U.S. sales, expanding patient access in PFIC and reinforcing the product’s market penetration in core indications (Zacks).
As of June 30, 2025, Mirum held $321.7 million in cash, cash equivalents and investments—up from $298.6 million at the end of Q1—providing sufficient runway to fund key pipeline milestones through 2026 without immediate financing needs (Zacks).
Research and development expenses surged 41% year-over-year to $46.1 million and selling, general and administrative expenses rose 28.7% to $63.3 million in Q2 2025, reflecting elevated cash burn as Mirum scales its commercial and R&D programs (Zacks).
Despite strong top-line growth, Mirum reported a net loss of $0.12 per share in Q2 2025, underscoring that profitability remains a distant goal amid ongoing operating losses (Zacks).
Mirum’s valuation hinges on high-risk late-stage pipeline catalysts—volixibat VISTAS topline data due Q2 2026 and LIVMARLI EXPAND enrollment completion in 2026—exposing investors to binary clinical risks and potential delays (BioSpace).
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
MIRM Financial Performance
Revenues and expenses
MIRM Earnings Performance
Company profitability
MIRM News
AllArticlesVideos
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire5 days ago
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Business Wire3 weeks ago
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Mirum Pharmaceuticals stock?
Mirum Pharmaceuticals (MIRM) has a market cap of $3.7B as of September 16, 2025.
What is the P/E ratio for Mirum Pharmaceuticals stock?
The price to earnings (P/E) ratio for Mirum Pharmaceuticals (MIRM) stock is 0 as of September 16, 2025.
Does Mirum Pharmaceuticals stock pay dividends?
No, Mirum Pharmaceuticals (MIRM) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Mirum Pharmaceuticals dividend payment date?
Mirum Pharmaceuticals (MIRM) stock does not pay dividends to its shareholders.
What is the beta indicator for Mirum Pharmaceuticals?
Mirum Pharmaceuticals (MIRM) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.